Beverly L Alston-Smith

发表

HCV DAA Therapy in Persons with HIV-HCV Genotype 1 Coinfection Results in High Rate of Sustained Virologic Response and Heterogeneity in Normalization of Soluble Markers of Immune Activation.

D. Anthony, L. Smeaton, D. Wyles, 2020, Journal of Infectious Diseases.

Progression of carotid artery intima–media thickening in HIV-infected and uninfected adults

W. K. Henry, J. Currier, P. Tebas, 2007, AIDS.

Carotid artery intima–media thickness and HIV infection: traditional risk factors overshadow impact of protease inhibitor exposure

W. K. Henry, J. Currier, H. Hodis, 2005, AIDS.

Rationale and design of the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE).

Michael T. Lu, C. Fichtenbaum, P. Douglas, 2019, American heart journal.

Effect of Concomitantly Administered Rifampin on the Pharmacokinetics and Safety of Atazanavir Administered Twice Daily

A. Zolopa, D. Haas, E. Acosta, 2007, Antimicrobial Agents and Chemotherapy.

Effect of nandrolone decanoate therapy on weight and lean body mass in HIV-infected women with weight loss: a randomized, double-blind, placebo-controlled, multicenter trial.

J. Currier, K. Mulligan, R. Clark, 2005, Archives of internal medicine.

Randomized controlled study of tenofovir and adefovir in chronic hepatitis B virus and HIV infection: ACTG A5127

V. Johnson, S. Swindells, R. Pollard, 2006, Hepatology.

Immune response to hepatitis B vaccine in HIV-infected subjects using granulocyte-macrophage colony-stimulating factor (GM-CSF) as a vaccine adjuvant: ACTG study 5220.

J. Aberg, M. Peters, E. Overton, 2010, Vaccine.

Pitavastatin to Prevent Cardiovascular Disease in HIV Infection.

Michael T. Lu, G. Bloomfield, C. Fichtenbaum, 2023, The New England journal of medicine.

Successful recruitment of a multi-site international randomized placebo-controlled trial in people with HIV with attention to diversity of race and ethnicity: critical role of central coordination

A. Rancourt, C. Fichtenbaum, P. Douglas, 2020, HIV research & clinical practice.

Antiretroviral therapies in women after single-dose nevirapine exposure.

M. Hughes, R. Schooley, J. Mellors, 2010, The New England journal of medicine.

Rationale and design of the Mechanistic Substudy of the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE): Effects of pitavastatin on coronary artery disease and inflammatory biomarkers.

Michael T. Lu, C. Fichtenbaum, P. Douglas, 2019, American heart journal.

The effect of long-term storage on measured plasma lactate concentrations and prospective lactate results from a multicenter trial of antiretroviral therapy

R. Parker, D. Kitch, K. Mulligan, 2005, Clinical chemistry and laboratory medicine.

Hepatotoxicity and Gastrointestinal Intolerance When Healthy Volunteers Taking Rifampin Add Twice-Daily Atazanavir and Ritonavir

A. Zolopa, D. Haas, E. Acosta, 2009, Journal of acquired immune deficiency syndromes.

Nevirapine- Versus Lopinavir/Ritonavir-Based Initial Therapy for HIV-1 Infection among Women in Africa: A Randomized Trial

M. Hughes, R. Schooley, J. Mellors, 2012, PLoS medicine.

Low Rate of CMV End-Organ Disease in HIV-Infected Patients Despite Low CD4+ Cell Counts and CMV Viremia: Results of ACTG Protocol A5030

C. Crumpacker, S. Spector, D. Jabs, 2009, HIV clinical trials.

T-cell Activation Is Correlated With Monocyte Activation in HCV/HIV Coinfection and Declines During HCV Direct-Acting Antiviral Therapy

D. Anthony, D. Wyles, M. Sulkowski, 2021, Open forum infectious diseases.

Effects of Pitavastatin on Coronary Artery Disease and Inflammatory Biomarkers in HIV

C. Fichtenbaum, T. Burdo, T. Mayrhofer, 2024, JAMA cardiology.

Pilot study of low-dose interleukin-2, pegylated interferon-alpha 2b, and ribavirin for the treatment of hepatitis C virus infection in patients with HIV infection.

C. Fichtenbaum, M. Glesby, R. Bassett, 2005, The Journal of infectious diseases.

Characteristics of REPRIEVE Trial Participants Identifying Across the Transgender Spectrum.

P. Douglas, E. Gardner, Kathleen V Fitch, 2020, The Journal of infectious diseases.

Raltegravir pharmacokinetics before and during treatment with ombitasvir, paritaprevir/ritonavir plus dasabuvir in adults with human immunodeficiency virus‐1 and hepatitis C virus coinfection: AIDS Clinical Trials Group sub‐study A5334s

S. Rosenkranz, D. Wyles, M. Sulkowski, 2020, British journal of clinical pharmacology.

Alendronate with calcium and vitamin D supplementation is safe and effective for the treatment of decreased bone mineral density in HIV

S. Swindells, G. McComsey, P. Tebas, 2007, AIDS.